Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine-Reference-Cited by-同舟云学术

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

Published:2018-12-07 Issue:4 Volume:124 Page:479-490
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Cid‐Silva Purificación¹²,Fernández‐Bargiela Noelia²,Margusino‐Framiñán Luis¹²,Balboa‐Barreiro Vanesa³,Mena‐De‐Cea Álvaro¹⁴,López‐Calvo Soledad⁴,Vázquez‐Rodríguez Pilar⁴,Martín‐Herranz Isabel²,Míguez‐Rey Enrique¹,Poveda Eva⁵,Castro‐Iglesias Ángeles¹⁴

Affiliation:

1. Division of Clinical Virology Biomedical Research Institute of A Coruña (INIBIC)‐Universitary Hospital of A Coruña (CHUAC), SERGAS, University of A Coruña (UDC) A Coruña Spain

2. Service of Pharmacy Universitary Hospital of A Coruña (CHUAC), SERGAS A Coruña Spain

3. Clinical Epidemiology and Biostatistics Unit Biomedical Research Institute of A Coruña (INIBIC)‐Universitary Hospital of A Coruña (CHUAC), SERGAS, University of A Coruña (UDC) A Coruña Spain

4. Service of Infectious Internal Medicine Universitary Hospital of A Coruña (CHUAC), SERGAS A Coruña Spain

5. Group of Virology and PathogenesisGalicia Sur Health Research Institute (IIS Galicia Sur)‐Complexo Hospitalario Universitario de Vigo, SERGAS‐UVigo Vigo Spain

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13161

Reference34 articles.

1. The end of AIDS: HIV infection as a chronic disease

2. Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016

3. The challenge of aging and pharmacoterapeutic complexity in the HIV + patient;Morillo‐Verdugo R;Farm Hosp,2018

4. Cardiovascular risk and dyslipidemia among persons living with HIV: a review

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks;Alimentary Pharmacology & Therapeutics;2023-10-31

2. Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV;Journal of Medical Science;2023-09-26

3. Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins;JAMA Network Open;2023-09-11

4. Lipid profile changes associated with antiretroviral therapies in a real-world cohort;Farmacia Hospitalaria;2023-09

5. Lipid profile changes associated with antiretroviral therapies in a real-world cohort;FARM HOSP;2023